These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 24300813)

  • 1. [Clinical characteristics of multiple sclerosis in the Tomsk region].
    Alifirova VM; Titiova MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):15-7. PubMed ID: 24300813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
    Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
    J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dynamics of clinical presentations of multiple sclerosis in Amur region for the period of 1960 to 2005].
    Karnaukh VN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):75-8. PubMed ID: 19891350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A retrospective study of patients with early onset of multiple sclerosis in Omskaya Oblast].
    Kakulia AV; Rozhdestvenskiĭ AS; Khanokh EV; Delov RA; Filipenko ML
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):16-21. PubMed ID: 22677674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics, course and prognosis of spinal multiple sclerosis.
    Nociti V; Cianfoni A; Mirabella M; Caggiula M; Frisullo G; Patanella AK; Sancricca C; Angelucci F; Tonali PA; Batocchi AP
    Spinal Cord; 2005 Dec; 43(12):731-4. PubMed ID: 16010274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple sclerosis in Eastern Siberia: a 20-year prospective study in Novosibirsk city].
    Malkova NA; Shperling LP; Riabukhina OV; Merkulova EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():11-6. PubMed ID: 17172229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis.
    Alroughani R; Ahmed SF; Al-Hashel J
    Pediatr Neurol; 2015 Dec; 53(6):508-12. PubMed ID: 26383244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demographics and clinical characteristics of multiple sclerosis in Kuwait.
    Alroughani R; Ahmed SF; Al-Hashel J
    Eur Neurol; 2014; 72(3-4):181-5. PubMed ID: 25227152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
    Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH
    Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low degree of cortical pathology is associated with benign course of multiple sclerosis.
    Calabrese M; Favaretto A; Poretto V; Romualdi C; Rinaldi F; Mattisi I; Morra A; Perini P; Gallo P
    Mult Scler; 2013 Jun; 19(7):904-11. PubMed ID: 23069877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular comorbidities in the onset and progression of multiple sclerosis.
    Tettey P; Simpson S; Taylor BV; van der Mei IA
    J Neurol Sci; 2014 Dec; 347(1-2):23-33. PubMed ID: 25454639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The morbidity of multiple sclerosis.
    Swingler RJ; Compston DA
    Q J Med; 1992 Apr; 83(300):325-37. PubMed ID: 1631264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Smoking as a risk factor of development and progression of multiple sclerosis (a review and experimental data)].
    Sharafutdinova LR; Magzhanov RV; Rakhmatullin AR; Bakhtiiarova KZ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):18-22. PubMed ID: 24416808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiological characteristics of multiple sclerosis in the Kabardino-Balkaria Republic].
    Zikhova AR; Berezgova LM; Tlapshokova LB; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):5-7. PubMed ID: 24300811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical epidemiology of multiple sclerosis in Moscow. Descriptive epidemiology in population of one region of Moscow].
    Boĭko AN; Kukel' TM; Lysenko MA; Vdovichenko TV; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):8-14. PubMed ID: 24300812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation.
    Veugelers PJ; Fisk JD; Brown MG; Stadnyk K; Sketris IS; Murray TJ; Bhan V
    Mult Scler; 2009 Nov; 15(11):1286-94. PubMed ID: 19965558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.